Simple and predictive bioassays for potency and dose-standardization are still sought by the biopharmaceutical industry. Automatable, homogeneous bioassays are desirable because they can help to streamline this evaluative process. Implementing straightforward predictive automation-friendly bioassays as demonstrated in this article allows effective assessment of anti-TNFα and likely other biologicals for quality control. This article was reprinted in Promega Notes 100 with permission from Genetic Engineering News.
Promega Notes 100, 19–21.